Q-Bank Breakdown: Asthma pathophysiology & treatment — Why Every Answer Choice Matters

You’re doing a q-bank block on asthma and it feels like every question is “wheeze + cough = pick albuterol”… until the test writers start slipping in distractors that are almost right. This post breaks down a classic Step-style asthma vignette the way you should review it: pick the best answer and learn why the other options are wrong (or right in a different scenario).

Tag: Pulmonary > Obstructive Lung Disease

---

The Vignette (USMLE-Style)

A 19-year-old woman comes to clinic for episodic shortness of breath and chest tightness for the past year. Symptoms are worse at night and with exercise. She has allergic rhinitis and eczema. Exam is normal between episodes. Spirometry shows:

• FEV$_1$/FVC: decreased
• FEV$_1$: 70% predicted
• After inhaled bronchodilator: FEV$_1$ increases by 18%

Which of the following is the most appropriate long-term therapy?

A. Inhaled albuterol as needed
B. Inhaled ipratropium
C. Inhaled corticosteroid daily
D. Oral prednisone daily
E. Montelukast monotherapy
F. Omalizumab
G. Inhaled salmeterol monotherapy
H. Propranolol

---

Step 1: Identify the Core Diagnosis

This is asthma based on:

• Episodic symptoms with triggers (nighttime, exercise)
• Atopy (eczema, allergic rhinitis)
• Obstructive pattern on spirometry (low FEV$_1$/FVC)
• Reversibility: FEV$_1$ increase $\ge$ 12% and $\ge$ 200 mL after bronchodilator strongly supports asthma (the stem gives 18%)

Pathophysiology in One Pass (High-Yield)

Asthma is due to airway hyperresponsiveness and reversible airflow obstruction from:

• Bronchoconstriction (acute)
• Mucus hypersecretion
• Airway edema/inflammation
• Airway remodeling (chronic): subepithelial fibrosis, smooth muscle hypertrophy → can make obstruction less reversible over time

Immunology buzzwords (Step 1 favorites):

• Th2 skew → IL-4 (IgE class switching), IL-5 (eosinophils), IL-13 (mucus)
• Eosinophils, mast cells
• Curschmann spirals and Charcot–Leyden crystals (eosinophil-derived) can show up in sputum

---

Step 2: Pick the Best Answer (and Why)

✅ Correct Answer: C. Inhaled corticosteroid daily

Her spirometry suggests asthma, and her symptoms are not described as “rare” or “only occasional.” With an FEV$_1$ around 70% predicted and nighttime symptoms implied, she fits at least persistent asthma. For persistent asthma, daily inhaled corticosteroids (ICS) are the foundation of long-term control.

Why ICS are the cornerstone

• They reduce airway inflammation
• Decrease mucus production
• Decrease airway hyperresponsiveness
• Reduce exacerbations and improve lung function over time

Mechanism (Step 1 version):

• Glucocorticoid receptor activation → altered gene transcription → ↓ inflammatory cytokines, ↓ eosinophils, ↓ vascular permeability

Classic adverse effects

• Oropharyngeal candidiasis, dysphonia
• Mitigation: spacer + rinse mouth after use

---

Step 3: Why Every Distractor Is There (and When It Would Be Right)

Below is the real value: learning the “if/then” logic behind wrong answers.

A. Inhaled albuterol as needed (SABA)

Why it’s tempting: it treats symptoms quickly.
Why it’s wrong here: SABA is rescue, not controller. For persistent asthma, you need an anti-inflammatory controller (ICS).

When it’s correct:

• Intermittent asthma (symptoms <2 days/week, nighttime <2/month, normal FEV$_1$ between episodes)
• Also used before exercise for exercise-induced bronchoconstriction

High-yield mechanism: $\beta_2$ agonist → ↑ cAMP → bronchodilation
Toxicity: tremor, tachycardia, hypokalemia

---

B. Inhaled ipratropium (SAMA)

Why it’s tempting: bronchodilator, used in obstructive lung disease.
Why it’s wrong: ipratropium is not first-line controller for asthma.

When it’s correct:

• COPD maintenance (more classic)
• Acute asthma exacerbation adjunct with SABA in the ED (especially moderate–severe)

Mechanism: muscarinic (M3) antagonism → ↓ bronchoconstriction
Side effects: dry mouth, urinary retention (minimal systemic absorption inhaled)

---

D. Oral prednisone daily

Why it’s tempting: steroids treat asthma inflammation.
Why it’s wrong: chronic oral steroids have major systemic toxicity and are reserved for severe, refractory asthma when other therapies fail.

When it’s correct:

• Acute exacerbation (short course of systemic steroids)
• Severe persistent asthma not controlled on maximal inhaled therapy (specialist territory)

Classic chronic steroid toxicities: osteoporosis, diabetes, adrenal suppression, cataracts, glaucoma, skin thinning, proximal myopathy

---

E. Montelukast monotherapy

Why it’s tempting: asthma + atopy; leukotrienes are involved.
Why it’s wrong: leukotriene receptor antagonists are generally adjuncts, and ICS are preferred first-line for persistent asthma.

When it’s correct (or reasonable):

• Aspirin-exacerbated respiratory disease (AERD): asthma + nasal polyps + aspirin sensitivity
• Exercise-induced bronchoconstriction prophylaxis
• Patients who can’t/won’t use ICS (less effective)

Mechanism: blocks CysLT$_1$ receptor → ↓ leukotriene-mediated bronchoconstriction and mucus
High-yield adverse effect: neuropsychiatric symptoms (boxed warning; know the association)

---

F. Omalizumab

Why it’s tempting: “allergic asthma” clues (eczema, rhinitis).
Why it’s wrong: it’s for moderate–severe persistent allergic asthma not controlled on standard therapy (ICS ± LABA), typically with elevated IgE and sensitization.

When it’s correct:

• Allergic asthma with frequent symptoms/exacerbations despite optimized controller therapy

Mechanism: anti-IgE monoclonal antibody → decreases free IgE and downstream mast cell activation
Risk: anaphylaxis (rare but tested)

---

G. Inhaled salmeterol monotherapy (LABA alone)

Why it’s tempting: long-acting bronchodilation sounds like “long-term control.”
Why it’s wrong (very high-yield): LABA monotherapy increases asthma-related deaths. LABAs must be paired with an ICS in asthma.

When it’s correct:

• COPD can use LABA alone
• Asthma: only as add-on therapy to ICS when not controlled

Mechanism: $\beta_2$ agonist bronchodilation (long-acting)

---

H. Propranolol

Why it’s tempting: sometimes q-banks test drug-induced bronchospasm.
Why it’s wrong: nonselective $\beta$-blockers ($\beta_2$ blockade) can precipitate bronchospasm and blunt response to albuterol.

When it’s relevant:

• A patient with asthma worsening after starting a nonselective $\beta$-blocker (propranolol, nadolol, timolol eye drops can also do it)
• If a $\beta$-blocker is required, use $\beta_1$-selective agents (metoprolol, atenolol) cautiously

---

Rapid-Fire High-Yield Table: Asthma Meds by Job

---

How This Shows Up on Step Questions

1) “Reversible obstruction” clue

If they give spirometry with bronchodilator response, mentally lock in:

• Obstructive baseline + reversibility → asthma

2) Symptoms drive step-up therapy

They’ll force you to choose between:

• “Just use albuterol” vs “start ICS”
• The trick: persistent symptoms = controller therapy

3) Monotherapy traps

• LABA alone in asthma = no
• Oral prednisone daily for routine control = no
• Montelukast alone = usually not first-line

---

Takeaway: The One-Sentence Rule

If the vignette suggests persistent asthma, the best long-term answer is almost always daily inhaled corticosteroids, and most distractors are either rescue meds, adjuncts, or for severe refractory disease.